Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 
• By Dexter Jie Yan
  
An equal allocation of study populations in multiregional trials is set to become a major hurdle for sponsors. (Shutterstock)

More from Complete Response Letters

More from China